CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients

Blood

Volumn 106, Issue 3, 2005, Pages 1008-1011

  Nishikawa, Hiroyoshi ^b   Jäger, Elke ^b   Ritter, Gerd ^b   Old, Lloyd J ^b   Gnjatic, Sacha ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; NY ESO 1 PROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CELL ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SEROCONVERSION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TUMOR IMMUNITY;

EID: 23044463715     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-02-0607     Document Type: Article

References (24)

1. Chen Y-T, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997;94:1914-1918.
2. Jager E, Chen Y-T, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187:265-270.
3. Jager E, Nagata Y, Gnjatic S, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A. 2000;97:4760-4765.
4. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A. 2003;100:8862-8867.
5. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-1164.
6. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol. 2001;2:816-822.
7. + suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2:389-400.
8. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562.
9. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 1999; 59:3128-3133.
10. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211-5218.
11. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci U S A. 2003;100: 10902-10906.
12. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61: 4766-4772.
13. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
14. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
15. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173:1444-1453.
16. Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J Immunol. 2004;172:5967-5972.
17. + T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000;191:625-630.
18. + T cell responses against viral and tumor antigens using T cells as novel target APC. J Immunol Methods. 2003;278:57-66.
19. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol. 2004;5:508-515.
20. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity. 2004;21:733-741.
21. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287-296.
22. + regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004; 20:107-118.
23. + T cell subset committed in vivo to suppress antigen-specific T cell responses without additional stimulation. Eur J Immunol. 2004;34:3016-3027.
24. + regulatory T cells. J Exp Med. 2005;201: 681-686.